The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Subconjunctival injection in various dosages
Intraocular injection in various dosages
Retina Consultants of Arizona
Phoenix, Arizona, United States
Texas Retina Associates
Arlington, Texas, United States
Safety and tolerability as assessed by visual acuity, intraocular pressure, slit lamp and indirect ophthalmoscope
Time frame: 12 months
Visual Acuity
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.